Beam Therapeutics (BEAM) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Beam Therapeutics (BEAM) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 1.4% versus a loss of 18.4%. Over five years, BEAM leads with a -73.4% price change compared with -77.6% for RXRX. Beam Therapeutics is the larger company by market cap ($2.56 billion vs $2.29 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | RXRX |
|---|---|---|
| Share price | $24.77 | $4.27 |
| Market cap | $2.56B | $2.29B |
| 1-day change | -1.82% | -7.78% |
| YTD return | -10.64% | +4.40% |
| 1-year return | -1.43% | -18.36% |
| 5-year return | -73.41% | -77.57% |
| EPS (TTM) | $-0.68 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.26 | $7.18 |
| 52-week low | $20.23 | $2.77 |
| Distance from 52-week high | -35.26% | -40.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.54% | +69.09% |
| Average volume | 1.94M | 20.28M |
| Shares outstanding | 103.29M | 535.34M |
| Employees | 540 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BEAM has outperformed RXRX by 16.9 percentage points over the past year.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
BEAM vs RXRX FAQ
Which is bigger, Beam Therapeutics or Recursion Pharmaceuticals?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.56B compared with $2.29B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, BEAM or RXRX?
BEAM returned -1.43% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.